Literature DB >> 1329374

A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates.

G Palù1, G Gerna, F Bevilacqua, A Marcello.   

Abstract

A number of HSV-2 isolates, sequentially recovered from ulcerative ano-genital lesions of an AIDS patient during a prolonged treatment with acyclovir (ACV), have been studied at the molecular level. All of them were highly resistant to ACV (ACV-r) and shown to be virtually deficient in thymidine kinase (TK) activity. The ACV-r phenotype was demonstrated to be due to the production of truncated TK polypeptide. Structural alteration of this gene, as shown in one isolate, was caused by a chain-terminating mutation that originated from a cytidine deletion at position 520 of the TK open reading frame. This mutation generated a TGA stop codon 27 nucleotides downstream. An additional isolate was also recovered following ACV discontinuation and after a cycle of treatment with foscarnet. This isolate had lost the ACV-r trait and was characterized by a wild type TK sequence and by the production of a functional enzyme. Data presented confirm that a prolonged treatment with acyclovir can easily select ACV-r HSV-2 isolates carrying a TK- phenotype caused by a frameshift mutation. Although recovered from lesions tributary of different myelomers, these isolates may belong to the same strain that has undergone multiple cycles of reactivation and has possibly mutated during its axonal route to the skin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329374     DOI: 10.1016/0168-1702(92)90105-i

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  10 in total

Review 1.  Molecular diagnosis of herpes simplex virus infections in the central nervous system.

Authors:  Y W Tang; P S Mitchell; M J Espy; T F Smith; D H Persing
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 4.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

5.  Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.

Authors:  Deborah Watson-Jones; Anna Wald; Connie Celum; Jairam Lingappa; Helen A Weiss; John Changalucha; Kathy Baisley; Clare Tanton; Richard J Hayes; Joshua O Marshak; Rula Green Gladden; David M Koelle
Journal:  J Clin Microbiol       Date:  2010-08-11       Impact factor: 5.948

6.  Comparative evaluation of colorimetric microtiter plate systems for detection of herpes simplex virus in cerebrospinal fluid.

Authors:  Y W Tang; P N Rys; B J Rutledge; P S Mitchell; T F Smith; D H Persing
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

7.  Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia.

Authors:  Kening Wang; Gowtham Mahalingam; Susan E Hoover; Erik K Mont; Steven M Holland; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

8.  Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir.

Authors:  J J Sasadeusz; F Tufaro; S Safrin; K Schubert; M M Hubinette; P K Cheung; S L Sacks
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 9.  Review article: the therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome.

Authors:  C M Wilcox; K E Mönkemüller
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171

Review 10.  Cellular Targets for the Treatment of Flavivirus Infections.

Authors:  Mohammad Khalid Zakaria; Tea Carletti; Alessandro Marcello
Journal:  Front Cell Infect Microbiol       Date:  2018-11-12       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.